Gabriel Pet Straps Ltd FY26 Results

Standalone Revenue: ₹177.23 crore
Consolidated Profit: ₹5.28 crore

Reader Takeaway: Stellar standalone growth driven by scaling operations; monitor acquisition's future impact.

What just happened

Gabriel Pet Straps Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a significant surge in its standalone operations.

Standalone revenue jumped approximately 474% to ₹177.23 crore (₹17,722.90 lakh) in FY 2026, compared to ₹30.84 crore (₹3,084.39 lakh) in FY 2025. Total standalone income grew by about 478% to ₹179.02 crore.

Standalone profit for the period saw a substantial increase of around 138%, reaching ₹3.71 crore (₹371.41 lakh) in FY 2026, up from ₹1.56 crore (₹155.81 lakh) in the previous fiscal year.

On a consolidated basis, revenue stood at ₹182.85 crore, with a profit of ₹5.28 crore.

The company also reported that its auditors provided an unmodified opinion on both standalone and consolidated financial results, indicating clean financial reporting.

Why this matters

The dramatic increase in standalone revenue and profit signifies significant operational scaling and growth for Gabriel Pet Straps. This performance suggests the company is effectively expanding its business.

Furthermore, the acquisition of a 95% stake in M/s Drug Centre through its wholly-owned subsidiary, Gabriel Ingrevia Limited, points towards an inorganic growth strategy. This move could open new avenues for revenue and market reach.

The backstory

Gabriel Pet Straps Limited is primarily engaged in the manufacturing and sale of pet straps. The company has been focused on expanding its operational capacity and market presence.

What changes now

The current financial results reflect the performance of the standalone business and previously established operations. The impact of the acquisition of M/s Drug Centre is not yet reflected as its business operations commenced after the reporting period ended March 31, 2026.

Investors will be looking for future reports to quantify the contribution of M/s Drug Centre to the consolidated financials.

Risks to watch

The primary watch point is the future performance and integration of the acquired entity, M/s Drug Centre. Since its operations began post-March 31, 2026, its impact on consolidated revenue and profitability is yet to be seen and needs to be monitored closely.

Context metrics (time-bound)

• Standalone Revenue FY26: ₹177.23 crore (up ~474% from FY25)
• Standalone Profit FY26: ₹3.71 crore (up ~138% from FY25)
• Acquisition: 95% stake in M/s Drug Centre acquired March 20, 2026.

What to track next

Investors should track the quarterly results to assess the integration and financial contribution of M/s Drug Centre. The company's ability to sustain its standalone growth trajectory while effectively leveraging its new acquisition will be key.